Clinical Trial

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-01; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2024-03-18
Trial Details
NCT Number NCT06155084
Lead Sponsor Hinova Pharmaceuticals Inc.
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 84 participants
Start Date 2023-12-26
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-22